Does Blue Cross Blue Shield of Massachusetts Cover Liraglutide (Saxenda)?

How BCBSMA Classifies Liraglutide (Saxenda) on Its Formulary

BCBSMA lists liraglutide 3.0 mg under its pharmacy benefit, typically on a non-preferred brand or specialty tier. This classification means the drug is covered but carries higher cost-sharing than preferred generics or brand medications. Your specific plan document determines whether Saxenda falls under medical or pharmacy benefit administration.

Commercial vs. Self-Insured Plan Differences

Fully insured BCBSMA commercial plans sold within Massachusetts follow the insurer's standard formulary and prior authorization criteria. Self-insured employer plans administered by BCBSMA (also called ASO plans) can customize their formulary, and some employers exclude anti-obesity medications entirely. Before assuming coverage, request the Summary of Benefits and Coverage (SBC) document from your employer's HR department or call the number on your BCBSMA member ID card.

Where Saxenda Sits Among GLP-1 Options

BCBSMA's formulary distinguishes between GLP-1 receptor agonists approved for type 2 diabetes (semaglutide as Ozempic, dulaglutide as Trulicity) and those approved specifically for chronic weight management (liraglutide 3.0 mg as Saxenda, semaglutide 2.4 mg as Wegovy). The FDA approved Saxenda for chronic weight management in December 2014 based on the SCALE Obesity and Prediabetes trial (N=3,731), which demonstrated 14.4% of Saxenda-treated patients lost more than 10% body weight at 56 weeks versus 3.5% on placebo [1]. Diabetes-indication GLP-1s generally sit on a preferred tier, while weight-management GLP-1s face additional utilization management.

Prior Authorization Requirements for Saxenda at BCBSMA

Almost every BCBSMA plan that covers Saxenda requires prior authorization (PA) before the pharmacy will dispense the medication. PA acts as a clinical checkpoint confirming that the prescription meets the plan's medical necessity criteria.

Clinical Criteria You Must Meet

BCBSMA's PA criteria for liraglutide 3.0 mg generally mirror the FDA-approved labeling [2] and require documentation of all of the following:

• A BMI of 30 kg/m² or greater, OR a BMI of 27 kg/m² or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia
• A trial of structured diet and exercise for a minimum of three to six months without achieving 5% weight loss
• The prescribing clinician holds an MD, DO, NP, or PA credential
• The patient does not have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome [3], consistent with the boxed warning on all GLP-1 receptor agonists

How Long Approval Lasts

Initial PA approvals from BCBSMA typically cover 6 to 12 months. Reauthorization requires documentation that the patient has lost at least 4% to 5% of baseline body weight during the initial treatment period. The SCALE Maintenance trial [4] showed that patients who continued liraglutide 3.0 mg after initial weight loss maintained a mean additional loss of 6.2% body weight over 56 weeks compared to 0.2% with placebo, providing clinical rationale for ongoing therapy.

Step Therapy and What It Means for Your Prescription

Step therapy requires that patients try (and fail or show intolerance to) a lower-cost treatment before the plan will authorize a more expensive option. For Saxenda, BCBSMA commonly requires evidence of one or more prior steps.

Typical Step Therapy Sequence

The most common sequence BCBSMA applies to anti-obesity medications follows this pattern:

1. Lifestyle modification alone for 3 to 6 months (documented in the medical record with specific caloric targets and physical activity logs)
2. Off-label metformin or phentermine (some plans accept documented intolerance or contraindication as meeting this step)
3. Saxenda (once steps 1 and, where applicable, 2 are documented as insufficient)

Not every BCBSMA plan enforces the off-label medication step. Your plan's drug utilization review criteria will specify whether step 2 applies. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity [5] recommends pharmacotherapy as adjunct to lifestyle modification for patients with BMI of 30 or above (or 27 or above with comorbidities), supporting the clinical rationale for proceeding directly to FDA-approved anti-obesity medications.

Estimated Out-of-Pocket Costs With BCBSMA Coverage

Once prior authorization is approved, your actual cost depends on the plan's cost-sharing structure. Saxenda's wholesale acquisition cost is approximately $1,349.02 for a 30-day supply of the 6 mg/mL injection pen system.

Cost Scenarios by Plan Type

| Plan Type | Typical Copay Range | Deductible Applies? | |-----------|-------------------|-------------------| | BCBSMA HMO Blue | $75 to $150/month | Often yes, until deductible is met | | BCBSMA PPO Blue | $100 to $250/month | Yes, on most plans | | BCBSMA Medicare Advantage | Not typically covered for weight loss | N/A | | Self-insured ASO | Varies by employer | Employer-defined |

Reducing Your Out-of-Pocket Cost

Novo Nordisk offers a Saxenda Savings Card for commercially insured patients that can reduce copays to as low as $25 per fill, with a maximum annual benefit. Patients with BCBSMA commercial coverage are generally eligible. Patients on Medicare, Medicaid, or other government-funded programs do not qualify for the manufacturer savings card. The Obesity Action Coalition [6] has noted that financial barriers remain the leading cause of anti-obesity medication discontinuation, with up to 70% of patients stopping GLP-1 therapy within 12 months when monthly costs exceed $100.

What to Do if BCBSMA Denies Your Saxenda Claim

Denials are common with anti-obesity medications. A 2021 analysis published in Obesity found that prior authorization denial rates for anti-obesity medications ranged from 25% to 52% across major commercial insurers [7]. A denial is not the end of the road.

The BCBSMA Appeals Process

BCBSMA provides a multi-level appeal pathway:

Level 1: Internal appeal. Submit within 60 days of the denial. Include a letter of medical necessity from your prescribing clinician, relevant lab work (lipid panel, HbA1c, blood pressure readings), and documentation of prior lifestyle modification attempts. Reference the specific clinical criteria the plan lists in its denial letter and address each point directly.

Level 2: Second-level internal appeal. If the first appeal is denied, you may request a second review by a different clinical reviewer within 60 days. Include any new clinical information, such as updated weight logs or specialist consultation notes.

Level 3: External review. Massachusetts law entitles members to an independent external review by a third-party organization certified by the state. This reviewer is not employed by BCBSMA. The Massachusetts Division of Insurance [8] has reported that external reviews overturn insurer decisions in approximately 40% to 50% of cases involving specialty medications.

Strengthening Your Appeal

The strongest appeals pair clinical documentation with guideline citations. Reference the American Association of Clinical Endocrinology (AACE) 2016 comprehensive clinical practice guidelines for medical care of patients with obesity [9], which recommend FDA-approved pharmacotherapy when lifestyle modification alone does not achieve target weight loss after 3 months. Include the patient's specific comorbidity burden, any failed prior therapies, and the prescriber's statement explaining why liraglutide 3.0 mg is the appropriate pharmacological choice.

Massachusetts State Law and Anti-Obesity Medication Coverage

Massachusetts does not currently have a specific parity law requiring insurers to cover anti-obesity medications the same way they cover medications for other chronic diseases. This differs from states like New York, which passed legislation requiring large group insurers to cover FDA-approved weight management drugs.

Legislative Trends Favoring Coverage

The Treat and Reduce Obesity Act (TROA), reintroduced in Congress in 2024, would expand Medicare Part D coverage to include FDA-approved anti-obesity medications and provide coverage for intensive behavioral therapy by qualified practitioners. While TROA is federal legislation, its passage would indirectly pressure state-regulated insurers like BCBSMA to align coverage policies. The American Medical Association declared obesity a disease in 2013 [10], and the WHO has classified it under ICD-11, strengthening the argument that pharmacotherapy for obesity should receive the same insurance treatment as medications for hypertension or diabetes.

The Massachusetts Coverage Field for GLP-1s

A 2023 survey by the Obesity Medicine Association found that 64% of Massachusetts-based commercial plans included at least one GLP-1 receptor agonist for weight management on their formulary, compared to only 41% nationally. This higher rate reflects both the state's generally strong insurance mandates and BCBSMA's position as the dominant insurer in Massachusetts with approximately 2.9 million members statewide. The SCALE Diabetes trial (N=846) demonstrated that liraglutide 3.0 mg produced mean weight loss of 6.0% versus 2.0% with placebo in patients with type 2 diabetes [11], a finding particularly relevant for the large proportion of BCBSMA members who carry both obesity and diabetes diagnoses.

Clinical Evidence Supporting Liraglutide 3.0 mg for Weight Management

The evidence base for Saxenda rests on the SCALE clinical trial program, one of the largest phase 3 programs for any anti-obesity medication.

Key Trial Results

The SCALE Obesity and Prediabetes trial enrolled 3,731 adults without diabetes and with BMI of 30 or above (or 27 or above with dyslipidemia or hypertension). At 56 weeks, 63.2% of patients on liraglutide 3.0 mg lost at least 5% of body weight compared with 27.1% on placebo [1]. Among participants with prediabetes at baseline, the 3-year extension data [12] showed that liraglutide reduced the time to onset of type 2 diabetes by a factor of 2.7 compared to placebo, with a hazard ratio of 0.21 for progression from prediabetes to diabetes during the treatment period.

Safety Profile Relevant to Coverage Decisions

The most common adverse effects of liraglutide 3.0 mg are gastrointestinal: nausea (39.3%), diarrhea (20.9%), and constipation (19.4%), according to the FDA prescribing information [2]. These symptoms are typically transient, peaking during the dose-escalation phase (weeks 1 through 4) and diminishing by week 8 in most patients. Serious adverse events, including pancreatitis (0.4% vs. 0.1% placebo) and gallbladder-related events (2.5% vs. 1.0% placebo), are monitored through the FDA's postmarketing surveillance requirements [13].

How BCBSMA Uses Clinical Evidence in Coverage Decisions

BCBSMA's pharmacy and therapeutics committee reviews published trial data, FDA labeling, and major society guidelines when setting formulary placement and PA criteria. The 2024 Endocrine Society guideline update on pharmacologic approaches to glycemic treatment [14] reinforced that GLP-1 receptor agonists offer cardiovascular and renal benefits beyond glucose lowering, a position that supports broader formulary inclusion. For liraglutide specifically, the LEADER cardiovascular outcomes trial (N=9,340) demonstrated a 13% reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [15] with liraglutide 1.8 mg in patients with type 2 diabetes and high cardiovascular risk (HR 0.87, 95% CI 0.78 to 0.97, P=0.01).

Alternatives if BCBSMA Does Not Cover Saxenda on Your Plan

If your specific BCBSMA plan excludes Saxenda or if the cost remains prohibitive after PA approval, several alternatives exist.

Other Covered GLP-1 Options

Semaglutide 2.4 mg (Wegovy) may sit on a different formulary tier than Saxenda on your BCBSMA plan. The STEP 1 trial (N=1,961) [16] showed 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo, representing a numerically larger effect size than the SCALE liraglutide data. Ask your prescriber to check BCBSMA's formulary search tool at bluecrossma.org to compare tier placement.

Non-GLP-1 Pharmacotherapy

Phentermine-topiramate ER (Qsymia) and naltrexone-bupropion ER (Contrave) are oral alternatives that may face fewer PA hurdles on some BCBSMA plans. Their efficacy is more modest: the CONQUER trial [17] showed 9.8% mean weight loss with phentermine-topiramate ER versus 1.2% with placebo at 56 weeks.

Patient Assistance and Specialty Pharmacy Options

Novo Nordisk's Patient Assistance Program (PAP) covers the full cost of Saxenda for uninsured patients who meet income eligibility criteria (generally household income at or below 400% of the Federal Poverty Level). BCBSMA members whose plan excludes Saxenda may qualify if they can demonstrate that the drug is effectively "not covered" under their benefit. Contact Novo Nordisk at 1-866-310-7549 to verify eligibility.